PMID- 36366955
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 1443-1661 (Electronic)
IS  - 0915-5635 (Linking)
VI  - 35
IP  - 4
DP  - 2023 May
TI  - Endoscopic ablation therapy for the pancreatic neoplasms.
PG  - 430-442
LID - 10.1111/den.14468 [doi]
AB  - Recently, endoscopic ultrasound (EUS)-guided ablation therapy has been reported 
      as a less invasive therapy for patients with pancreatic neoplasms. Some ablation 
      techniques, including injective ablation (using ethanol or other ablative 
      agents), radiofrequency ablation (RFA), photodynamic therapy, and laser ablation, 
      have been described in the literature. Among these, injective ablation and RFA 
      are more frequently used for treating pancreatic neoplasms. Few studies have 
      evaluated the effectiveness of EUS-guided ethanol ablation (EUS-EA) for 
      potentially malignant solid neoplasms (neuroendocrine neoplasms or solid 
      pseudopapillary neoplasms) and have reported a complete response (CR) rate of 
      60-80%. In addition, the CR rate after EUS-RFA for these lesions has been 
      reported to be 55-100%, with no additional procedure-related adverse events 
      (AEs). Regarding the amelioration of the symptoms of an insulinoma, the success 
      rates of both the therapies were found to be excellent. Regarding complete tumor 
      ablation, EUS-RFA appeared to be superior to EUS-EA. Although EUS-RFA has been 
      reported as a safe treatment for pancreatic cancers, its effectiveness remains 
      inadequate. Some studies have examined the effectiveness of EUS-guided injection 
      ablation therapy for pancreatic cystic neoplasms (PCNs) and have reported CR 
      rates that range from 35% to 79%. Alcohol-free chemotherapeutic agent ablation 
      appears to be effective, with a low risk of AEs. However, studies on the 
      effectiveness of EUS-RFA for PCNs are limited. In the future, EUS-guided ablation 
      therapy could become a more widely used approach for potentially malignant and 
      malignant pancreatic lesions.
CI  - (c) 2022 Japan Gastroenterological Endoscopy Society.
FAU - Matsumoto, Kazuyuki
AU  - Matsumoto K
AUID- ORCID: 0000-0002-5102-7452
AD  - Department of Gastroenterology and Hepatology, Okayama University Hospital, 
      Okayama, Japan.
FAU - Kato, Hironari
AU  - Kato H
AUID- ORCID: 0000-0003-1120-292X
AD  - Department of Gastroenterology and Hepatology, Okayama University Hospital, 
      Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221213
PL  - Australia
TA  - Dig Endosc
JT  - Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy 
      Society
JID - 9101419
RN  - 3K9958V90M (Ethanol)
SB  - IM
MH  - Humans
MH  - *Pancreatic Neoplasms/diagnostic imaging/surgery/pathology
MH  - *Insulinoma/surgery
MH  - *Neuroendocrine Tumors/pathology
MH  - *Radiofrequency Ablation
MH  - Ethanol/therapeutic use
MH  - Endosonography/methods
OTO - NOTNLM
OT  - ablation techniques
OT  - endoscopic ultrasonography
OT  - ethanol
OT  - pancreatic neoplasms
OT  - radiofrequency ablation
EDAT- 2022/11/12 06:00
MHDA- 2023/05/15 06:42
CRDT- 2022/11/11 03:43
PHST- 2022/08/10 00:00 [received]
PHST- 2022/11/08 00:00 [accepted]
PHST- 2023/05/15 06:42 [medline]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/11 03:43 [entrez]
AID - 10.1111/den.14468 [doi]
PST - ppublish
SO  - Dig Endosc. 2023 May;35(4):430-442. doi: 10.1111/den.14468. Epub 2022 Dec 13.